

## Q4 FY26 Results

India Delivered Double-Digit Growth; North America Secured Approval for first AB-rated gVentolin

	Income from Operations	EBITDA	PAT
<b>Q4:</b>	<b>INR 6,541 Cr</b>	<b>INR 997 Cr</b> <b>(15.2% Margin)</b>	<b>INR 555 Cr</b> <b>(8.5% Margin)</b>
<b>FY26:</b>	<b>INR 28,163 Cr</b>	<b>INR 5,925 Cr</b> <b>(21.0% Margin)</b>	<b>INR 3,879 Cr</b> <b>(13.8% Margin)</b>

**Mumbai, May 13, 2026:** Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its audited consolidated financial results for the quarter ended March 31<sup>st</sup>, 2026.

### Key Highlights for the Quarter

- **One-India:** One India business grew at a robust 15% YoY with all 3 segments delivering double-digit-growth during the quarter. The Branded Prescription business sustained growth momentum in key chronic therapies, Trade Generics continued its steady growth and anchor brands of CHL continued to grow bigger.
- **North America:** Delivered quarterly revenue of \$ 155 Mn supported by demand in differentiated portfolio and a steady base business.
- **One Africa:** Growth momentum remained strong with overall quarterly revenue recording a robust 14% YoY growth in USD terms.
- **Emerging Markets and Europe:** The EMEU business delivered \$ 90 Mn during the quarter, while demonstrating resilience amid geopolitical uncertainties.
- **R&D investments:** Stood at INR 509 Cr or 7.8% of sales for the quarter, driven by product filings and development efforts.
- **Strong net cash:** Net cash position of INR 10,526 Cr; Debt primarily includes lease liabilities and working capital requirements.

"I am pleased to share that we continue to make considerable progress across our focused markets. In FY26, we recorded our highest-ever yearly revenue of INR 28,163 Cr, reflecting the strength of our core businesses despite certain markets facing near-term challenges. Our One-India business surpassed the INR 12,500 Cr annual revenue milestone. Key therapies in Branded Prescription business delivered robust double-digit growth, Trade Generics business sustained the strong growth momentum and anchor brands of Consumer Health Business maintained leadership position. The US business posted an annual revenue of USD 780 Mn supported by demand in our differentiated portfolio and a steady base business. In One Africa, we recorded a healthy annual growth of 7% YoY in USD terms, driven by firm performance across key markets. Emerging Markets and Europe crossed the USD 400 Mn+ annualised revenue threshold on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front".

**Achin Gupta**  
MD and Global CEO, Cipla Ltd

#### For Queries Contact:

**Corporate Communications**  
Heena Kanal  
CorpComm@cipla.com

**Investor Relations**  
Diksha Maheshwari  
Investor.Relations@cipla.com

**Cipla Ltd.**  
Cipla House,  
Peninsula Business Park,  
Ganpatrao Kadam Marg,  
Lower Parel, Mumbai-400013

### ❖ One India Business

#### **Branded Prescription:**

During the year, key therapies like Respiratory, Urology, Anti-diabetes and Cardiac recorded double-digit market\*\* growth with chronic mix at 60.2%. Foracort continued its strong performance breaching the INR 1,000 Cr+ threshold. Dytor has emerged as an INR 650+ Cr in-house cardiac brand, delivering 25% YoY growth in the IPM\*\*.

#### **Trade Generics:**

The business delivered strong double-digit growth during the year. This performance was supported by execution excellence in key therapies, new introductions and technological interventions.

#### **Consumer Health:**

Anchor brands of Nicotex, Omnigel and Cipladine maintained leadership positions in the respective market segments.

### ❖ North America

North America delivered an annual revenue of \$ 780 Mn, supported by demand in differentiated assets and a steady base business. During the year, the business advanced its portfolio with several key assets, including Liraglutide, Nintedanib, Dapagliflozin. Notably, the business received regulatory approval for the first AB-rated gVentolin with CGT, representing the first commercial MDI product to be manufactured from our U.S. facility.

### ❖ One Africa

One Africa delivered strong performance, achieving a healthy annual growth of 7% YoY in USD terms. In the Private Market###, secondary growth outpaced the market growth at 6.6% versus the market growth of 4.8%. This growth was propelled by uptick in key therapies, new launches as well as the expansion of OTC portfolio.

### ❖ Emerging Markets and Europe

Deep market focus strategy in Emerging Markets and Europe has laid a strong foundation, with the business surpassing the USD 400 Mn annual revenue milestone. This performance was led by expansion across both DTM and B2B categories, alongside consistent margin stability.

### ❖ Regulatory update

The USFDA completed inspections at our manufacturing facilities in Bommasandra (Bengaluru), Sitec (Navi Mumbai), and Medispray (Goa) facilities, with all of these sites receiving a 'VAI' or 'NAI' classification.

## Dividend Note

The Board of Directors of the Company at its meeting held on 13th May, 2026 has recommended a final dividend of ₹ 13/- per equity share (face value of ₹ 2 each) for the financial year ended 31st March, 2026. The dividend is subject to approval of the shareholders at the ensuing annual general meeting of the Company.

### QUARTERLY BUSINESS WISE SALES PERFORMANCE

Business (In INR Cr)	Q4FY26	Q4FY25	Y-o-Y Growth
One India (Rx + Gx +CHL <sup>^</sup> )	3,007	2,622	15%
North America	1,414	1,919	-26%
One Africa <sup>#</sup>	1,236	1,019	21%
<i>South Africa</i>	984	738	33%
Emerging Markets and Europe	819	895	-9%
API and Others	64	274	-77%
<b>Total</b>	<b>6,541</b>	<b>6,730</b>	<b>-3%</b>

### ANNUAL BUSINESS WISE SALES PERFORMANCE

Business (In INR Cr)	FY26	FY25	Y-o-Y Growth
One India (Rx + Gx + CHL <sup>^</sup> )	12,680	11,615	9%
North America	6,871	7,899	-13%
One Africa <sup>#</sup>	4,287	3,827	12%
<i>South Africa</i>	3,364	2,932	15%
Emerging Markets and Europe	3,576	3,305	8%
API and Others	749	902	-17%
<b>Total</b>	<b>28,163</b>	<b>27,548</b>	<b>2%</b>

<sup>^</sup> CHL – Cipla Health limited | <sup>#</sup> One Africa includes South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access

## CONSOLIDATED PROFIT & LOSS STATEMENT – Q4 FY26

In INR Cr	Q4FY26	Q4FY25
<b>Total Income from Operations</b>	<b>6,541</b>	<b>6,730</b>
<b>EBITDA</b>	<b>997</b>	<b>1,538</b>
% of Income from Operations	15.2%	22.8%
<b>PAT</b>	<b>555</b>	<b>1,222</b>

## CONSOLIDATED PROFIT & LOSS STATEMENT – FY26

In INR Cr	FY26	FY25
<b>Total Income from Operations</b>	<b>28,163</b>	<b>27,548</b>
<b>EBITDA</b>	<b>5,925</b>	<b>7,128</b>
% of Income from Operations	21.0%	25.9%
<b>PAT</b>	<b>3,879</b>	<b>5,273</b>

## BALANCE SHEET (Reported)

Key Balance Sheet Items (INR Cr)	Mar-26	Sep-25	Mar-25
<b>Equity</b>	<b>34,520</b>	<b>33,025</b>	<b>31,289</b>
<b>Total Debt<sup>#</sup></b>	<b>614</b>	<b>467</b>	<b>438</b>
<b>Inventory</b>	<b>6,597</b>	<b>6,160</b>	<b>5,642</b>
<b>Cash and Cash Equivalents*</b>	<b>11,140</b>	<b>10,368</b>	<b>10,807</b>
<b>Trade Receivables</b>	<b>5,620</b>	<b>6,902</b>	<b>5,506</b>
<b>Trade Payables</b>	<b>3,230</b>	<b>3,035</b>	<b>2,837</b>
<b>Net Tangible Assets</b>	<b>7,626</b>	<b>6,996</b>	<b>6,586</b>
<b>Goodwill and Intangibles</b>	<b>6,850</b>	<b>5,374</b>	<b>4,986</b>

<sup>#</sup> Total debt includes lease liabilities and borrowings | \* Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances | Figures have been rounded off

# Announcement

## Cipla to release Q4FY26 audited Financial Results on May 13, 2026

**Date: May 13, 2026**

- **1600 hrs IST – EARNINGS CONFERENCE CALL**

The Company will host an earnings conference call at 1600 hrs IST (1830 hrs SST/HKT, 1130 hrs BST, 0630 hrs US ET), during which the leadership team will discuss financial performance and take questions. A transcript of the conference call will be available at [www.cipla.com](http://www.cipla.com).

### Earnings Conference Call Dial-in Information

<b>Date and Time</b>	<b>May 13, 2026</b> at 1600 – 1700 hrs IST 1830 – 1930 hrs SST/HKT 1130 – 1230 hrs BST 0630 – 0730 hrs US ET
<b>Dial-in Numbers</b>	
Universal Access	Primary Access: <b>(+91 22 6280 1562)</b> <b>(+91 22 7115 8387)</b>
Diamond pass link	Click <a href="#">here</a> to register
Toll Free Number	USA: <b>18667462133</b> UK: <b>08081011573</b> Hong Kong: <b>800964448</b> Singapore: <b>8001012045</b>

### ABOUT CIPLA LTD

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3<sup>rd</sup> largest in pharma in India (IQVIA MAT Mar'26), second largest in the pharma prescription market in South Africa (IQVIA MAT Feb'26), and 3<sup>rd</sup> largest Respiratory player by prescription in the US Gx (IQVIA MAT Mar'26). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit [www.cipla.com](http://www.cipla.com), or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

**Disclaimer:** Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. Cipla Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.